47. Outcomes of definitive intensity-modulated radiotherapy for stage I-II laryngeal cancer
Main Article Content
Abstract
Early-stage laryngeal cancer can be effectively treated with either definitive radiotherapy or surgery. In recent years, intensity-modulated radiotherapy (IMRT) has been increasingly utilized due to its advantages in preserving vocal function and reducing radiation-induced toxicity to surrounding healthy tissues. This prospective–retrospective descriptive study included 38 male patients with stage I-II squamous cell carcinoma of the larynx treated with definitive IMRT at K Hospital and Hanoi Oncology Hospital between January 2021 and June 2025. The mean age was 66.34 ± 7.99 years old; 97.4% of tumors were located in the glottic region. The complete response rate was 94.7%, and the disease control rate reached 97.3%. The 3-year overall survival (OS) and disease-free survival (DFS) rates were 78% and 74%, respectively. Acute toxicities were mostly grade 1-2, including dermatitis and mucositis. These results indicate that definitive IMRT provides favorable clinical outcomes and effective disease control while maintaining voice function, suggesting it is a valuable treatment modality for early-stage laryngeal cancer.
Article Details
Keywords
Laryngeal cancer stage I-II, intensity-modulated radiotherapy
References
2. Lê Văn Quảng, Trịnh Lê Huy, Nguyễn Xuân Hậu. Ung thư đầu cổ. Hà Nội: Nhà xuất bản Y học; 2020.
3. Thái Hữu Dũng, Ngô Hoàng. Đánh giá kết quả phẫu thuật cắt bán phần thanh quản trên nhẫn chép điều trị ung thư thanh quản giai đoạn sớm. Tạp chí Tai Mũi Họng Việt Nam. 2023; 68(62): 4.
4. Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer. 2004; 100(9): 17861792. doi:10.1002/cncr.20181.
5. Forastiere AA, Ismaila N, Lewin JS, et al. Use of LarynxPreservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(11): 11431169. doi:10.1200/JCO.2017.75.7385.
6. Bhide SA, Nutting CM. Advances in radiotherapy for head and neck cancer. Oral Oncol. 2010; 46(6): 439441. doi:10.1016/j.oraloncology.2010.02.014.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2025. Accessed [August 19, 2025]. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
8. Jacobson BH, Johnson A, Grywalski C, et al. The Voice Handicap Index (VHI): development and validation. Am J Speech Lang Pathol. 1997; 6(3): 66-70. doi:10.1044/1058-0360.0603.66.
9. Quách Thanh Khánh. Xạ trị ung thư thanh môn giai đoạn sớm T1a, T1b [luận văn BSCK II]. TP. Hồ Chí Minh: Đại học Y Dược TP. Hồ Chí Minh; 2008.
10. Nguyễn Kỷ Cương. Đáp ứng với xạ trị giảm phân số liều trong ung thư thanh quản giai đoạn sớm. Tạp chí Y học Việt Nam. 2022.
11. Al-Mamgani A, Tans L, Van Rooij PH, Noever I, Levendag PC. Radiotherapy for T1-2N0 glottic carcinoma: a multivariate analysis of predictive factors for long-term outcome in 1050 patients and a prospective assessment of quality of life and voice handicap in 233 patients. Clin Otolaryngol. 2013; 38(4): 306-312.
12. Doluoglu S, Bayir O, Ocal B, Tatar EC, Korkmaz MH, Saylam G. Comparisons of the oncological results of transoral laser surgery and radiotherapy for early stage laryngeal squamous cell cancer: single-center long-term results. Ann Saudi Med. 2024; 44(4): 213-219. doi:10.5144/0256-4947.2024.213.
13. Tali TA, Amin F, Dar JA, Sofi SR, Sofi MA, Khan NA, Dar NA. Treatment outcome of early-stage laryngeal carcinoma treated with radical radiotherapy using different techniques: a retrospective study. Asian Pac J Cancer Care. 2023; 8(2): 269-273. doi:10.31557/apjcc.2023.8.2.269-273
14. Yamazaki H, Nishiyama K, Tanaka E, et al. Accelerated fractionation versus conventional fractionation radiotherapy for T1-2N0 glottic carcinoma in Japan: results of JCOG0701, a multi-institutional phase III randomized controlled trial. Int J Radiat Oncol Biol Phys. 2020; 106(5): 918-925.